NCT07928700
Phase 2 Study of pH Gastrilex™ (Enteric-Coated Amorphous Calcium Carbonate Capsules) in Moderate-to-Severe Crohn's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change From Baseline in Crohn's Disease Activity Index (CDAI)
Timeframe: Baseline and 12 weeks
Secondary (10)
Percentage of participants achieving clinical remission Clinical Remission
Percentage of participants achieving clinical response
Change From Baseline in Stool Frequency
Change From Baseline in Abdominal Pain Score
Endoscopic Response
Show 5 moreShow less
Change From Baseline in Quality of Life (SIBDQ)
Long-Term Maintenance of Clinical Remission
Long-Term Maintenance of Clinical Response
C-Reactive Protein (CRP) Normalization
Fecal Calprotectin ≤250 µg/g
Arms and interventions
PH Gastrilex™Experimental
PH Gastrilex™ (Amorphous Calcium Carbonate)
Placebo groupPlacebo comparator
Placebo Followed by PH Gastrilex™ (Amorphous Calcium Carbonate)
Drugs: PH Gastrilex, Placebo Comparator
Sites
1 site in 1 country
- Soroka University Medical CenterBeersheba, South, Israel